This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma AG, Basel, Switzerland.
50% improvement from baseline in the initial Bath Ankylosing Spondylitis Disease Activity Index
Reference
Purmonen T, et al. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. ClinicoEconomics and Outcomes Research : 15 Feb 2019. Available from: URL: https://doi.org/10.2147/CEOR.S192235
Rights and permissions
About this article
Cite this article
Secukinumab cost-effective option in ankylosing spondylitis. PharmacoEcon Outcomes News 822, 31 (2019). https://doi.org/10.1007/s40274-019-5683-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5683-2